- 1.Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998–1003.
10.1016/S0161-6420(98)96025-0Crossref, Google Scholar
- 2.No authors listed. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12):1796–1806.
10.1001/archopht.1985.01050120030015Crossref, Google Scholar
- 3.Diabetic Retinopathy Clinical Research NetworkElman MJ, Aiello LP, Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064–1077.
10.1016/j.ophtha.2010.02.031Crossref, Google Scholar
- 4.Nguyen QD, Brown DM, Marcus DM, Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789–801.
10.1016/j.ophtha.2011.12.039Crossref, Google Scholar
- 5.Rajendram R, Fraser-Bell S, Kaines A, A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012; 130(8):972–979.
10.1001/archophthalmol.2012.393Crossref, Google Scholar
- 6.Brown DM, Schmidt-Erfurth U, Do DV, Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015; 122(10):2044–52.
10.1016/j.ophtha.2015.06.017Crossref, Google Scholar
- 7.Dugel P. EARLY: Anti-VEGF treatment response at week 12 and long term outcomes in DME.
Paper presented at the American Academy of Ophthalmology Retina Subspecialty Day; November 13–17, 2015; Las Vegas, NV. Google Scholar
- 8.Gonzales V, Augustin A, Campbell J, EARLY: Anti-VEGF treatment response at week 12 and long term outcomes in DME.
Paper presented at World Ophthalmology Congress; February 5–9, 2016; Guadalajara, Mexico. Google Scholar
- 9.Boyer DS, Yoon YH, Belfort R, Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121(10):1904–1914.
10.1016/j.ophtha.2014.04.024Crossref, Google Scholar
- 10.Campochiaro PA, Brown DM, Pearson A, Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012; 119(10):2125–2132.
10.1016/j.ophtha.2012.04.030Crossref, Google Scholar
- 11.Bressler SB, Qin H, Beck RW, Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012; 130(9):1153–1161.
10.1001/archophthalmol.2012.1107Crossref, Google Scholar
- 12.Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115(9):1447–1459.
10.1016/j.ophtha.2008.06.015Crossref, Google Scholar
- 13.Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delayed system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina. 2015; 35(8):1604–1614.
10.1097/IAE.0000000000000533Crossref, Google Scholar
- 14.Figueira J, RESPOND study: Interim six month results.
Presented at the 2015 EURETINA Congress; September 17–20, 2015; Nice, France. Google Scholar
- 15.Campochiaro PA. Results of the AKB-9778 in the treatment of Diabetic retinopathy: Results from the TIME-2 Study.
Presented at Subspecialty Day, American Academy of Ophthalmology; November 2015, Las Vegas, NV. Google Scholar
- 16.Singer MA. Results of the Optimeyes phase 2 study.
Presented at World of Ophthalmology Congress; February 2016; Guadalajara, Mexico. Google Scholar
- 17.A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema. ClinicalTrials.gov identifier: NCT02302079. Google Scholar
- 18.A phase 2 randomized, controlled, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin and focal laser photocoagulation in the treatment of diabetic macular edema. ClinicalTrials.gov identifier: NCT02348918. Google Scholar
- 19.Anti-vascular endothelial growth factor plus anti-angiopoietin 2 in fixed combination therapy: evaluation for the treatment of diabetic macular edema (RUBY). ClinicalTrials.gov identifier: NCT02712008. Google Scholar
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username